Karabulut S, Akşit E, Tas F, Ciftci R, Aydiner A, Yildiz I, Keskin S, Eralp Y, Yasasever C T, Vatansever S, Disci R, Saip P
Department of Medical Oncology, Institute of Oncology, Istanbul University, Capa, 34390, Istanbul, Turkey,
Tumour Biol. 2014 May;35(5):4323-9. doi: 10.1007/s13277-013-1567-4. Epub 2014 Jan 5.
The role of molecular markers in ovarian cancer is still a matter of debate. Protease-activated receptor-1 (PAR1) might be a good marker in some types of malignant tumors and might provide useful information in diagnosis and prognosis. The objective of this study was to evaluate the serum levels of PAR1 in regard to diagnostic, predictive, and prognostic value in epithelial ovarian cancer (EOC) patients. Forty-four EOC patients were enrolled in this study. Serum PAR1 levels were determined by enzyme-linked immunosorbent assay (ELISA) method. Twenty-five age- and sex-matched healthy controls were included in the analysis. The median age of patients was 58 years old, ranging from 22 to 83 years, where most of them had advanced disease (stage III-IV) (n = 40, 91%). The median serum PAR1 values were significantly elevated in patients compared to healthy controls (1.52 ng/ml vs. 1.13 ng/ml) (p = 0.03), whereas any clinical variables including response to chemotherapy did not associate with serum assay (p > 0.05). Progression-free survival (PFS) and overall survival (OS) of patients who did not respond to chemotherapy nor had platinum resistance in relapsed disease were poorer in the analyses. On the other hand, serum PAR1 levels showed no significant adverse effect on either PFS or OS (p = 0.43 and p = 0.49, respectively). These results proved that baseline serum PAR1 levels of patients with EOC were significantly higher than those of healthy people. However, these assays suggested no predictive or prognostic value in this group of patients.
分子标志物在卵巢癌中的作用仍存在争议。蛋白酶激活受体-1（PAR1）在某些类型的恶性肿瘤中可能是一个良好的标志物，并且可能在诊断和预后方面提供有用信息。本研究的目的是评估上皮性卵巢癌（EOC）患者血清PAR1水平在诊断、预测和预后方面的价值。44例EOC患者纳入本研究。采用酶联免疫吸附测定（ELISA）法测定血清PAR1水平。分析中纳入了25名年龄和性别匹配的健康对照。患者的中位年龄为58岁，范围为22至83岁，其中大多数患有晚期疾病（III-IV期）（n = 40，91%）。与健康对照相比，患者的血清PAR1中位值显著升高（1.52 ng/ml对1.13 ng/ml）（p = 0.03），而包括化疗反应在内的任何临床变量均与血清检测无关（p > 0.05）。在分析中，对化疗无反应且在复发疾病中无铂耐药的患者的无进展生存期（PFS）和总生存期（OS）较差。另一方面，血清PAR1水平对PFS或OS均无显著不良影响（分别为p = 0.43和p = 0.49）。这些结果证明，EOC患者的基线血清PAR1水平显著高于健康人。然而，这些检测在这组患者中未显示出预测或预后价值。
